Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com
StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a report issued on Friday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Price Performance Shares of NASDAQ AKTX opened at $3.83 on Friday. The firm has a fifty day simple moving average of $3.52 and […]
More Stories
SECURITY COUNCIL LIVE: Ambassadors to meet over deepening Lebanon crisis, with region ‘on the brink of catastrophe’
The Security Council is due to hold an emergency meeting in New York on Friday from 3pm, following Israeli strikes...
Lebanon: WHO appeals for more support for civilians as crises intensify
The international community must come to the aid of Lebanon in the face of back-to-back crises and spillover from the...
News from the WHO: Governments progress on negotiations for a pandemic agreement to boost global preparedness for future emergencies https://ift.tt/Lp23hDT September 20, 2024 at 07:00AM
Published on September 20, 2024 at 07:00AM View on website
Middle East: Regional crisis risks engulfing Syria, UN envoy warns
The escalating regional tensions are drawing Syria deeper into conflict, the UN Special Envoy for the country warned on Tuesday,...
Steelcase (NYSE:SCS) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS
Steelcase (NYSE:SCS – Get Free Report) announced its earnings results on Wednesday. The business services provider reported $0.39 earnings per...
Lawmakers Mull Revamp of Secret Service Funding, Policy After Trump Assassination Attempts
By Joseph Lord and Arjun Singh WASHINGTON, D.C.—In the aftermath of an apparent second attempted assassination of former President Donald...